



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2017





HIV/AIDS Drug Treatment Program

Monthly Report

© 2017 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

August 2017

N = 7259



Health Authority	Male	Female	All
FRASER	1388	393	1781
INTERIOR	377	101	478
NORTHERN	133	83	216
VANCOUVER COASTAL	3409	451	3860
VANCOUVER ISLAND	728	161	889
	6035	1189	7224
		Unknown/not stated:	35
		Total:	7259

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2012 - August 2017)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2012 - August 2017)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (August 2012 - August 2017)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (August 2012 - August 2017)






1.6 Percent Distribution of Active Participants by CD4 Count (August 2012 - August 2017)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(August 2012 - August 2017)






1.8 Active and Inactive Participants
(August 2012 - August 2017)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (August 2012 - August 2017)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2012 - August 2017)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(August 2012 - August 2017)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (August 2012 - August 2017)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2012 - August 2017)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2012 - August 2017)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(August 2012 - August 2017)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (August 2012 - August 2017)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(August 2012 - August 2017)






1.18 Baseline CD4 for Antiretroviral First Starts
(August 2012 - August 2017)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(August 2012 - August 2017)**






1.20 Cumulative Resistance Testing Results by Resistance Category (August 2012 - August 2017)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2012 - August 2017)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2017
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	25	5	0	5	5	720	5	<40	3
1988	25	7	0	7	7	550	7	<40	3
1989	24	57	2	59	51	530	56	<40	3
1990	23	62	1	63	57	480	63	<40	3
1991	23	39	3	42	32	530	39	<40	3
1992	23	69	7	76	61	540	75	<40	3
1993	22	144	16	160	144	520	157	<40	3
1994	20	91	15	106	94	570	105	<40	3
1995	21	120	24	144	116	550	136	<40	3
1996	19	361	60	421	362	590	404	<40	3
1997	17	294	37	331	298	640	321	<40	3
1998	16	214	46	260	222	550	248	<40	3
1999	16	171	40	211	188	560	204	<40	3
2000	16	135	35	170	151	540	162	<40	3
2001	16	128	34	162	134	570	147	<40	3
2002	15	137	29	166	140	550	157	<40	3
2003	14	168	29	197	167	578	185	<40	3
2004	13	176	40	216	178	574	198	<40	3
2005	12	193	49	242	205	580	229	<40	3
2006	11	206	44	250	206	570	232	<40	3
2007	10	269	50	319	266	615	296	<40	3
2008	9	307	70	377	321	620	353	<40	3
2009	8	338	77	415	351	630	391	<40	3
2010	7	291	72	363	312	640	347	<40	3
2011	6	348	73	421	371	680	399	<40	3
2012	5	289	64	353	308	660	342	<40	3
2013	4	286	70	356	296	625	337	<40	3
2014	3	307	57	364	301	690	346	<40	3
2015	2	315	56	371	312	655	349	<40	3
2016	1	317	68	385	330	620	372	<40	3
2017	0	202	26	228	212	539	221	<40	3
Total:		6046	1194	7240					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	6970	737	2261	<40	2023	590
FEB-2016	6989	735	2064	<40	1865	590
MAR-2016	6995	736	2155	<40	1958	590
APR-2016	7014	733	2053	<40	1864	580
MAY-2016	7043	747	2071	<40	1885	590
JUN-2016	7062	739	2178	<40	1991	610
JUL-2016	7052	749	1949	<40	1760	600
AUG-2016	7069	750	2068	<40	1877	590
SEP-2016	7108	751	2214	<40	1999	600
OCT-2016	7138	747	2153	<40	1935	600
NOV-2016	7169	742	2110	<40	1902	580
DEC-2016	7192	751	1871	<40	1707	620
JAN-2017	7182	748	2323	<40	2067	590
FEB-2017	7134	755	1914	<40	1732	590
MAR-2017	7186	746	2200	<40	2008	600
APR-2017	7180	747	1965	<40	1750	590
MAY-2017	7227	748	2280	<40	2026	590
JUN-2017	7247	753	2119	<40	1913	600
JUL-2017	7241	755	1965	<40	1700	590
AUG-2017	7259	758	2103	<40	1760	590

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	1510	2280	116	<40	104	465
FEB-2016	1502	2325	83	353	74	380
MAR-2016	1509	2311	87	130	83	440
APR-2016	1513	2294	87	<50	74	360
MAY-2016	1497	2377	79	<40	69	350
JUN-2016	1508	2371	72	76	56	505
JUL-2016	1532	2316	81	<50	76	455
AUG-2016	1556	2225	94	158	78	360
SEP-2016	1543	2286	96	240	80	360
OCT-2016	1517	2450	73	<40	70	415
NOV-2016	1514	2500	73	1007	58	380
DEC-2016	1515	2530	52	122	44	480
JAN-2017	1531	2500	88	140	78	417
FEB-2017	1587	2290	79	1387	69	400
MAR-2017	1542	2452	101	635	89	360
APR-2017	1560	2415	95	517	85	420
MAY-2017	1531	2544	82	148	69	420
JUN-2017	1523	2649	77	153	67	490
JUL-2017	1547	2557	68	376	56	515
AUG-2017	1558	2538	79	150	67	530

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2016	6940	1510	9	16	152	168	-12	12409
FEB-2016	6960	1502	5	18	178	163	20	12437
MAR-2016	6968	1509	9	23	171	173	8	12471
APR-2016	6987	1513	6	20	166	157	19	12505
MAY-2016	7018	1497	7	21	161	142	31	12536
JUN-2016	7032	1508	12	34	163	167	14	12579
JUL-2016	7015	1532	11	25	136	157	-17	12611
AUG-2016	7031	1556	10	40	165	172	16	12671
SEP-2016	7073	1543	5	27	179	151	42	12714
OCT-2016	7101	1517	11	22	161	138	28	12745
NOV-2016	7127	1514	20	27	181	160	26	12791
DEC-2016	7149	1515	11	25	154	142	22	12831
JAN-2017	7144	1531	21	22	140	144	-5	12863
FEB-2017	7104	1587	10	24	136	185	-40	12897
MAR-2017	7152	1542	17	19	187	139	48	12923
APR-2017	7146	1560	12	20	144	155	-6	12955
MAY-2017	7204	1531	7	22	172	127	58	12989
JUN-2017	7225	1523	9	24	149	137	21	13019
JUL-2017	7221	1547	6	14	134	146	-4	13038
AUG-2017	7240	1558	6	25	157	155	19	13068

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2016	58	6405	446	61	6970	0.83%	91.89%	6.40%	0.88%	100.00%
FEB-2016	59	6436	435	59	6989	0.84%	92.09%	6.22%	0.84%	100.00%
MAR-2016	54	6442	438	61	6995	0.77%	92.09%	6.26%	0.87%	100.00%
APR-2016	54	6464	439	57	7014	0.77%	92.16%	6.26%	0.81%	100.00%
MAY-2016	57	6495	437	54	7043	0.81%	92.22%	6.20%	0.77%	100.00%
JUN-2016	60	6499	447	56	7062	0.85%	92.03%	6.33%	0.79%	100.00%
JUL-2016	57	6496	442	57	7052	0.81%	92.12%	6.27%	0.81%	100.00%
AUG-2016	57	6509	447	56	7069	0.81%	92.08%	6.32%	0.79%	100.00%
SEP-2016	58	6546	447	57	7108	0.82%	92.09%	6.29%	0.80%	100.00%
OCT-2016	58	6578	445	57	7138	0.81%	92.15%	6.23%	0.80%	100.00%
NOV-2016	61	6603	446	59	7169	0.85%	92.10%	6.22%	0.82%	100.00%
DEC-2016	62	6635	437	58	7192	0.86%	92.26%	6.08%	0.81%	100.00%
JAN-2017	61	6615	443	63	7182	0.85%	92.11%	6.17%	0.88%	100.00%
FEB-2017	60	6579	440	55	7134	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	438	59	7186	0.83%	92.25%	6.10%	0.82%	100.00%
APR-2017	59	6633	429	59	7180	0.82%	92.38%	5.97%	0.82%	100.00%
MAY-2017	62	6667	439	59	7227	0.86%	92.25%	6.07%	0.82%	100.00%
JUN-2017	57	6693	439	58	7247	0.79%	92.36%	6.06%	0.80%	100.00%
JUL-2017	61	6686	433	61	7241	0.84%	92.34%	5.98%	0.84%	100.00%
AUG-2017	61	6689	449	60	7259	0.84%	92.15%	6.19%	0.83%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>		
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	
JAN-2016	4 19%	2818 42%	4 19%	2485 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	0 0%	17 81%	4165 62%
FEB-2016	10 36%	2851 42%	9 32%	2519 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	0 0%	18 64%	4135 61%
MAR-2016	9 26%	2877 43%	7 21%	2542 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	0 0%	26 76%	4112 61%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	5 0%	22 65%	4103 60%	
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	0 0%	6 0%	23 74%	4120 61%	
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	1 2%	9 0%	31 72%	4117 60%	
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	0 0%	9 0%	23 72%	4113 60%	
AUG-2016	11 19%	2936 43%	11 19%	2626 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	6 10%	22 0%	42 71%	4097 60%	
SEP-2016	14 33%	2969 43%	12 28%	2659 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	3 7%	25 0%	27 63%	4102 60%	
OCT-2016	11 35%	2997 43%	11 35%	2689 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	0 0%	26 0%	20 65%	4098 59%	
NOV-2016	17 37%	3023 44%	17 37%	2722 39%	0 0%	78 1%	0 0%	7 0%	0 0%	6 0%	0 0%	35 1%	29 63%	4088 59%	
DEC-2016	7 18%	3058 44%	7 18%	2753 40%	0 0%	77 1%	0 0%	6 0%	0 0%	6 0%	0 0%	35 1%	33 83%	4077 59%	
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4051 58%	
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3982 58%	
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%	
APR-2017	13 41%	3115 45%	12 38%	2835 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3963 57%	
MAY-2017	9 26%	3158 45%	9 26%	2880 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3934 56%	
JUN-2017	6 20%	3168 45%	6 20%	2901 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3900 56%	
JUL-2017	7 37%	3197 46%	7 37%	2927 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%	
AUG-2017	6 20%	3221 46%	4 13%	2956 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3834 54%	

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2016	17	81%	3848	57%
FEB-2016	18	64%	3828	57%
MAR-2016	25	74%	3809	56%
APR-2016	22	65%	3812	56%
MAY-2016	23	74%	3834	56%
JUN-2016	32	74%	3829	56%
JUL-2016	23	72%	3830	56%
AUG-2016	48	81%	3831	56%
SEP-2016	29	67%	3847	56%
OCT-2016	20	65%	3848	56%
NOV-2016	29	63%	3852	56%
DEC-2016	33	83%	3843	55%
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3792	55%
MAY-2017	25	74%	3799	54%
JUN-2017	24	80%	3799	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3763	53%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1128 34%	1 9%	326 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1155 35%	1 8%	317 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1197 37%	0 0%	293 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1220 38%	0 0%	282 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1235 38%	0 0%	283 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1689 53%	11 79%	1242 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1663 52%	26 90%	1254 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1643 52%	9 82%	1269 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1615 51%	9 82%	1263 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
NOV-2016	0 0%	9 0%	3 16%	1588 51%	15 79%	1282 41%	1 5%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
DEC-2016	0 0%	9 0%	3 17%	1588 50%	15 83%	1305 41%	0 0%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1313 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1307 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1328 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1483 49%	5 71%	1319 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1352 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1361 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1438 47%	6 100%	1360 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1416 47%	21 95%	1395 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%
NOV-2016	0	0%	1	0%
DEC-2016	0	0%	1	0%
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	996 41%	0 0%	307 13%	1 25%	854 35%	1 25%	257 11%
APR-2016	3 33%	990 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	969 41%	1 25%	299 13%	2 50%	836 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	295 13%	0 0%	830 35%	2 29%	262 11%
SEP-2016	2 50%	949 41%	0 0%	295 13%	0 0%	819 35%	2 50%	265 11%
OCT-2016	1 20%	944 41%	2 40%	300 13%	1 20%	814 35%	1 20%	269 12%
NOV-2016	7 88%	936 41%	1 13%	294 13%	0 0%	812 35%	0 0%	269 12%
DEC-2016	7 70%	927 40%	0 0%	290 13%	0 0%	805 35%	3 30%	273 12%
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	898 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	889 40%	0 0%	273 12%	1 11%	787 35%	4 44%	271 12%
MAY-2017	3 75%	878 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	837 39%	0 0%	264 12%	0 0%	780 36%	0 0%	283 13%
AUG-2017	1 100%	817 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	6 55%	1020 44%	4 36%	458 20%	0 0%	66 3%	1 9%	821 35%	0 0%	1 0%
FEB-2016	7 64%	1062 45%	4 36%	468 20%	0 0%	60 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1115 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1153 47%	4 22%	491 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1182 47%	4 24%	493 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	517 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1305 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1412 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%
NOV-2016	18 72%	1452 52%	5 20%	580 21%	0 0%	53 2%	2 8%	756 27%	0 0%	1 0%
DEC-2016	9 75%	1479 52%	2 17%	587 21%	0 0%	53 2%	1 8%	762 27%	0 0%	1 0%
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1619 55%	2 13%	602 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1656 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1727 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	12 75%	1758 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	8 73%	1790 58%	3 27%	593 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	13 72%	1822 58%	4 22%	597 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2016	2285	32.78	1944	27.89	1609	23.08	158	2.27	61	0.88	913	13.10
FEB-2016	2279	32.61	1925	27.54	1668	23.87	153	2.19	59	0.84	905	12.95
MAR-2016	2266	32.39	1903	27.21	1706	24.39	154	2.20	61	0.87	905	12.94
APR-2016	2244	31.99	1894	27.00	1757	25.05	154	2.20	57	0.81	908	12.95
MAY-2016	2256	32.03	1887	26.79	1781	25.29	157	2.23	54	0.77	908	12.89
JUN-2016	2255	31.93	1877	26.58	1811	25.64	152	2.15	56	0.79	911	12.90
JUL-2016	2225	31.55	1865	26.45	1847	26.19	150	2.13	57	0.81	908	12.88
AUG-2016	2210	31.26	1839	26.01	1913	27.06	142	2.01	56	0.79	909	12.86
SEP-2016	2191	30.82	1831	25.76	1977	27.81	144	2.03	57	0.80	908	12.77
OCT-2016	2169	30.39	1829	25.62	2033	28.48	146	2.05	57	0.80	904	12.66
NOV-2016	2174	30.33	1817	25.35	2074	28.93	143	1.99	59	0.82	902	12.58
DEC-2016	2181	30.33	1808	25.14	2102	29.23	143	1.99	58	0.81	900	12.51
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1755	24.42	2222	30.92	134	1.86	59	0.82	883	12.29
APR-2017	2108	29.36	1745	24.30	2260	31.48	133	1.85	59	0.82	875	12.19
MAY-2017	2109	29.18	1738	24.05	2308	31.94	132	1.83	59	0.82	881	12.19
JUN-2017	2116	29.20	1719	23.72	2350	32.43	132	1.82	58	0.80	872	12.03
JUL-2017	2102	29.03	1694	23.39	2387	32.97	130	1.80	61	0.84	867	11.97
AUG-2017	2092	28.82	1683	23.19	2408	33.17	130	1.79	60	0.83	886	12.21

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	23	4	3	4	7	5	350
APR-2016	20	2	1	2	2	9	580
MAY-2016	21	2	1	3	3	12	510
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370
NOV-2016	27	3	4	5	7	8	390
DEC-2016	25	4	1	5	3	11	410
JAN-2017	22	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2016	11048	3054
FEB-2016	11141	3135
MAR-2016	11201	3183
APR-2016	11248	3217
MAY-2016	11308	3266
JUN-2016	11364	3297
JUL-2016	11407	3332
AUG-2016	11452	3338
SEP-2016	11479	3342
OCT-2016	11510	3366
NOV-2016	11552	3387
DEC-2016	11582	3398
JAN-2017	11603	3419
FEB-2017	11630	3428
MAR-2017	11682	3478
APR-2017	11708	3493
MAY-2017	11750	3519
JUN-2017	11780	3535
JUL-2017	11814	3566
AUG-2017	11855	3594

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants August 2017

N = 7259

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2017

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2017

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2017

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2017

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2017

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	35	48	25
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	92	50	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	349	462	264	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	38
	50+	*	*	82
Total HSDA:	177	235	139	
Total HA:		631	837	478

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	64	65	*
	35-49	172	196	*
	50+	390	571	*
Total HA:		631	837	478

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	494	665	377
Female	137	172	101

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	478	53	590	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	19	*
	5 years or more	5	*
	<5 years	11	*
	Total HSDA:	35	25
KOOTENAY BOUNDARY	10 years or more	38	25
	5 years or more	19	16
	<5 years	13	9
	Total HSDA:	70	50
OKANAGAN	10 years or more	191	136
	5 years or more	81	64
	<5 years	77	64
	Total HSDA:	349	264
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	92	65
	5 years or more	38	34
	<5 years	47	40
	Total HSDA:	177	139
Total HA:		631	478

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	340	238
	5 years or more	143	118
	<5 years	148	122
Total HA:		631	478

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	37	53	14	23
KOOTENAY BOUNDARY	64	112	22	35
OKANAGAN	202	750	64	275
THOMPSON/CARIBOO/SHUSWAP	127	453	34	121
Total:	430	1368	134	454

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	94

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	26	27	18
	35-49	105	117	76
	50+	196	263	157
	Total HSDA:	333	413	256
FRASER NORTH	0-19	13	13	*
	20-34	113	114	*
	35-49	344	384	*
	50+	506	795	*
	Total HSDA:	976	1306	765
FRASER SOUTH	0-19	9	9	6
	20-34	96	98	66
	35-49	370	423	303
	50+	464	683	385
	Total HSDA:	939	1213	760
Total HA:		2248	2932	1781

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	28	28	14
	20-34	235	239	175
	35-49	819	924	644
	50+	1166	1741	948
Total HA:		2248	2932	1781

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1712	2262	1388
Female	536	670	393

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1781	50	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	168	123
	5 years or more	99	81
	<5 years	66	52
	Total HSDA:	333	256
FRASER NORTH	10 years or more	485	352
	5 years or more	242	191
	<5 years	249	222
	Total HSDA:	976	765
FRASER SOUTH	10 years or more	452	354
	5 years or more	248	206
	<5 years	239	200
	Total HSDA:	939	760
Total HA:		2248	1781

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1105	829
	5 years or more	589	478
	<5 years	554	474
Total HA:		2248	1781

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	132	447	40	96
FRASER NORTH	238	1490	58	261
FRASER SOUTH	204	1226	46	343
Total:	574	3163	144	700

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	179
FRASER NORTH	649
FRASER SOUTH	521
Total:	1349

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	22
	35-49	*	*	68
	50+	*	*	189
	Total HSDA:		326	467
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		161	207
VANCOUVER	0-19	47	50	5
	20-34	450	461	348
	35-49	1487	1696	1087
	50+	2596	4358	2013
	Total HSDA:	4580	6565	3453
Total HA:		5067	7239	3860

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	51	54	6
	20-34	502	514	391
	35-49	1614	1840	1189
	50+	2900	4831	2274
Total HA:		5067	7239	3860

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4458	6363	3409
Female	607	874	451

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3860	52	600	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	169	138
	5 years or more	75	66
	<5 years	82	75
	Total HSDA:	326	279
RICHMOND	10 years or more	78	55
	5 years or more	39	32
	<5 years	44	41
	Total HSDA:	161	128
VANCOUVER	10 years or more	2433	1754
	5 years or more	1222	931
	<5 years	925	768
	Never on ART	0	0
	Total HSDA:	4580	3453
Total HA:	5067	3860	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2680	1947
5 years or more	1336	1029
<5 years	1051	884
Never on ART	0	0
Total HA:	5067	3860

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	153	388	56	100
RICHMOND	42	274	14	98
VANCOUVER	556	10288	214	5355
Total:	751	10950	284	5553

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	114

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		300	419
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		116	153
SOUTH VANCOUVER ISLAND	0-19	5	5	*
	20-34	57	60	*
	35-49	199	234	*
	50+	431	668	*
	Total HSDA:		692	967
Total HA:		1108	1539	889

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	5
	20-34	94	100	69
	35-49	318	365	258
	50+	686	1064	557
Total HA:		1108	1539	889

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	902	1254	728
Female	206	285	161

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	889	53	520	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	142	118
	5 years or more	73	59
	<5 years	85	72
	Total HSDA:	300	249
NORTH VANCOUVER ISLAND	10 years or more	59	48
	5 years or more	28	23
	<5 years	29	24
	Total HSDA:	116	95
SOUTH VANCOUVER ISLAND	10 years or more	367	264
	5 years or more	161	135
	<5 years	164	146
	Total HSDA:	692	545
Total HA:		1108	889

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	568	430
	5 years or more	262	217
	<5 years	278	242
Total HA:		1108	889

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	179	802	78	210
NORTH VANCOUVER ISLAND	125	251	43	78
SOUTH VANCOUVER ISLAND	193	1629	43	547
Total:	497	2682	164	835

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	44
NORTH VANCOUVER ISLAND	32
SOUTH VANCOUVER ISLAND	104
Total:	180

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	5
	35-49	*	*	19
	50+	*	*	24
	Total HSDA:		68	103
NORTHERN INTERIOR	0-19	7	7	*
	20-34	21	24	*
	35-49	73	90	*
	50+	84	135	*
	Total HSDA:		185	256
Total HA:		292	406	216

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	32	37	*
	35-49	112	146	*
	50+	139	214	*
Total HA:		292	406	216

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	179	253	133
Female	113	153	83

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	216	49	525	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	16	8
	5 years or more	15	9
	<5 years	8	7
	Total HSDA:	39	24
NORTH WEST	10 years or more	23	13
	5 years or more	31	26
	<5 years	14	9
	Total HSDA:	68	48
NORTHERN INTERIOR	10 years or more	63	40
	5 years or more	64	55
	<5 years	58	49
	Total HSDA:	185	144
Total HA:		292	216

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	102	61
5 years or more	110	90
<5 years	80	65
Total HA:	292	216

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	33	59	7	10
NORTH WEST	66	149	18	28
NORTHERN INTERIOR	102	414	16	178
Total:	201	622	41	216

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	12
NORTHERN INTERIOR	23
Total:	42

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	34	*
	THOMPSON/CARIBOO/SHUSWAP	*	41	*
	Total HA:	53	92	43
FRASER	FRASER EAST	32	41	24
	FRASER NORTH	50	82	41
	FRASER SOUTH	77	106	58
	Total HA:	159	229	123
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	47	22
	RICHMOND	9	14	7
	VANCOUVER	506	819	418
	Total HA:	541	880	447
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	76	43
	NORTH VANCOUVER ISLAND	15	24	12
	SOUTH VANCOUVER ISLAND	33	73	28
	Total HA:	98	173	83
NORTHERN	NORTH EAST	8	10	6
	NORTH WEST	32	58	25
	NORTHERN INTERIOR	67	100	60
	Total HA:	107	168	91
Total:		958	1542	787

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	594	984	481
Female	364	558	306

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	787	50	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

